Jason Karlawish
speaker
1,378 appearances
5 recordings
1 series
first heard Feb 2021
last heard Dec 2023
Jason Karlawish’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
So it moved amyloid endpoints as these drugs generally do.
But more importantly, I kind of think it moved uh Tau measures as well.
Well I'll I'll continue on, as I say, people uh adults uh with uh either mild cognitive impairment, so cognitive impairment that's detectable but causing inefficiencies in daily life, or mild stage dementia, uh meaning uh some disability.
Uh mini metal cutoff, I forget precisely, but I think it was uh low twenties was the cutoff, the base the lower cutoff.
Um you had to have a definite impairment on a m memory a pretty intensive measure of memory called the logical memory test.
And as I say, uh had to have evidence of elevated amyloid by a PET scan.
Uh met those criteria got in.
Am I missing anything, Ken, or anyone?
so this is a group of people that have some inefficiencies or my or impairments at higher level IADLs.
So someone's got to do the finances, but they're still doing the cooking, etc.
No troubles with BADL stereotypically.
Yeah, yeah.
That is correct, yes.
CMS does does not cover PET scans as of yet.
They're gonna re-look at that decision in a week or two, uh whether they'll PET scans.
That's right.
I that's uh there's no contesting that.
As did etichetamab, as did many of these drugs.
But yes, the production of amyloid was well documented and very clear.
Yeah.
Showing 501–520 of 1,378 · page 26 of 69
← Previous
Next →